CVRX

+ Watchlist + Portfolio

CVRx, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.82
52-Week Range: $2.20 – $11.30
Market Cap: $75.66M
P/E (TTM): —
EPS (TTM): -1.97
Dividend Yield: —

Advanced Metrics

Price/Book: 3.79
PEG Ratio: —
Return on Equity: -133.45%
Return on Assets: -28.70%
Gross Margin: 86.92%
Operating Margin: -82.92%
Profit Margin: -84.93%
Current Ratio: 8.04
Debt/Equity: 2.98
Total Debt: $59.39M
Free Cash Flow: $-23.80M
Revenue Growth: 15.60%
Earnings Growth: —
Enterprise Value: $69.93M

CVRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$22.47M	$39.30M	$51.29M	$56.65M
Cost of Revenue	$5.00M	$6.26M	$8.33M	$8.31M
Gross Profit	$17.47M	$33.04M	$42.96M	$48.34M
Research & Development	$9.95M	$11.63M	$11.13M	$11.13M
Selling, General & Admin	$50.05M	$64.51M	$91.32M	$88.47M
Operating Expenses	$60.00M	$76.14M	$102.45M	$99.61M
Operating Income	-$42.53M	-$43.10M	-$59.49M	-$51.27M
EBITDA	-$40.74M	-$38.73M	-$54.89M	-$46.74M
Pretax Income	-$41.32M	-$41.05M	-$59.91M	-$53.32M
Income Tax	$109.00K	$147.00K	$55.00K	-$18.00K
Net Income	-$41.43M	-$41.20M	-$59.97M	-$53.31M
Diluted EPS	-2.02	-1.99	-2.65	-2.04
Diluted Shares	20.53M	20.75M	22.60M	26.08M

CVRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$106.19M	$90.57M	$105.93M	$75.71M
Receivables	$5.50M	$7.55M	$9.27M	$10.66M
Inventory	$6.96M	$10.98M	$12.11M	$12.21M
Current Assets	$122.88M	$112.09M	$129.81M	$101.65M
Total Assets	$124.94M	$115.23M	$133.41M	$104.79M
Current Liabilities	$8.09M	$7.86M	$10.76M	$13.32M
Long-Term Debt	$6.75M	$29.22M	$49.27M	$49.51M
Total Debt	$7.09M	$30.61M	$50.43M	$50.50M
Total Liabilities	$15.76M	$39.28M	$62.36M	$65.47M
Retained Earnings	-$436.18M	-$477.38M	-$537.35M	-$590.65M
Shareholders' Equity	$109.18M	$75.95M	$71.06M	$39.32M
Working Capital	$114.79M	$104.23M	$119.05M	$88.33M

CVRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$42.68M	-$39.02M	-$39.14M	-$40.17M
Capital Expenditure	-$685.00K	-$591.00K	-$1.36M	-$580.00K
Free Cash Flow	-$43.36M	-$39.61M	-$40.51M	-$40.75M
Depreciation & Amortisation	$412.00K	$522.00K	$619.00K	$756.00K
Stock-Based Compensation	$3.89M	$6.30M	$19.05M	$11.05M
Investing Cash Flow	-$685.00K	-$591.00K	-$1.36M	-$580.00K
Financing Cash Flow	$7.49M	$23.98M	$55.87M	$10.52M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$35.87M	-$15.63M	$15.37M	-$30.23M

CVRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$12.35M	$13.59M	$14.69M	$16.02M	$14.77M
Cost of Revenue	$2.04M	$2.14M	$1.94M	$2.20M	$1.89M
Gross Profit	$10.31M	$11.45M	$12.75M	$13.82M	$12.88M
Research & Development	$2.52M	$2.47M	$3.15M	$3.00M	$3.08M
Selling, General & Admin	$21.23M	$23.36M	$21.88M	$22.01M	$21.96M
Operating Expenses	$23.75M	$25.83M	$25.02M	$25.01M	$25.04M
Operating Income	-$13.44M	-$14.38M	-$12.27M	-$11.18M	-$12.16M
EBITDA	-$12.13M	-$13.07M	-$11.20M	-$10.34M	-$11.36M
Pretax Income	-$13.77M	-$14.74M	-$12.87M	-$11.94M	-$13.12M
Income Tax	-$5.00K	-$3.00K	-$3.00K	-$7.00K	$1.00K
Net Income	-$13.77M	-$14.74M	-$12.87M	-$11.93M	-$13.12M
Diluted EPS	-0.53	-0.57	-0.49	-0.46	-0.50
Diluted Shares	25.88M	26.07M	26.17M	26.22M	26.36M

CVRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$102.67M	$95.03M	$85.12M	$75.71M	$72.30M
Receivables	$9.01M	$7.15M	$8.21M	$10.66M	$9.10M
Inventory	$11.67M	$11.72M	$11.39M	$12.21M	$12.40M
Current Assets	$126.13M	$116.14M	$107.89M	$101.65M	$96.75M
Total Assets	$129.59M	$119.56M	$111.33M	$104.79M	$99.73M
Current Liabilities	$8.51M	$9.69M	$11.22M	$13.32M	$9.49M
Long-Term Debt	$49.33M	$49.39M	$49.45M	$49.51M	$58.49M
Total Debt	$50.42M	$50.54M	$50.52M	$50.50M	$59.40M
Total Liabilities	$60.23M	$61.63M	$63.27M	$65.47M	$70.62M
Retained Earnings	-$551.11M	-$565.85M	-$578.72M	-$590.65M	-$603.77M
Shareholders' Equity	$69.36M	$57.93M	$48.05M	$39.32M	$29.11M
Working Capital	$117.63M	$106.46M	$96.67M	$88.33M	$87.26M

CVRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.77M	-$7.94M	-$9.71M	-$9.76M	-$12.16M
Capital Expenditure	-$114.00K	-$103.00K	-$295.00K	-$68.00K	-$122.00K
Free Cash Flow	-$12.88M	-$8.04M	-$10.00M	-$9.83M	-$12.29M
Depreciation & Amortisation	$184.00K	$193.00K	$194.00K	$185.00K	$205.00K
Stock-Based Compensation	$2.46M	$2.92M	$2.89M	$2.79M	$2.92M
Investing Cash Flow	-$114.00K	-$103.00K	-$295.00K	-$68.00K	-$122.00K
Financing Cash Flow	$9.62M	$392.00K	$103.00K	$410.00K	$8.88M
Share Repurchases	—	—	—	—	-$43.00K
Net Change in Cash	-$3.27M	-$7.65M	-$9.90M	-$9.42M	-$3.40M

Market Snapshot

About

CVRx, Inc. is a medical device company focused on developing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company's lead product, the Barostim system, is designed to treat patients with heart failure and resistant hypertension by stimulating baroreceptors in the carotid artery. CVRx has received regulatory approvals in the United States and Europe for specific indications. The company continues to conduct clinical studies to expand the applications of its baroreflex activation therapy technology.